GLP-1s

Hims & Hers Health is partnering with Novo Nordisk to expand access to FDA-approved GLP-1 weight loss medications through its U.S. platform. The agreement includes Ozempic injections in 0.5-, 1- and 2-milligram  doses, as well as Wegovy injections in 1.7-…

Eli Lilly has launched Employer Connect, a platform that offers employers a direct route to offer Zepbound coverage to workers at a list price of $449 per month, bypassing traditional pharmacy benefits. The platform pairs employers with more than 15…

GLP-1 receptor agonists may reduce the risk of developing and dying from substance use disorders, a study found. The study, led by researchers at St. Louis-based WashU Medicine and published March 4 in The BMJ, analyzed data from more than…

Novo Nordisk has received a second warning letter from the FDA in less than a month, this time over an advertisement promoting its blockbuster diabetes drug Ozempic. In a Feb. 26 letter, the FDA said a direct-to-consumer television advertisement titled…

The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The letters cite violations including claims implying compounded products are the same as FDA-approved drugs, and advertising…

GLP-1 drugs may slightly raise the risk of osteoporosis, according to a pair of new studies. In one study, presented March 2 at the American Academy of Orthopaedic Surgeons’ annual meeting, researchers evaluated five years of medical records from more…

Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is eligible to receive up to…

Walgreens has expanded its virtual care platform to include weight management services, offering $49 clinician-guided visits for eligible adults using GLP-1 therapies. The new Walgreens Weight Management program is open to self-pay patients ages 18-64 who are overweight or have…

Novo Nordisk will reduce the U.S. list price of Wegovy, Ozempic and Rybelsus to $675 per month starting Jan. 1, 2027. The change constitutes a list price reduction of approximately 50% for Wegovy and 35% for Ozempic across all doses,…

A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss. The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema…